Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 1/20 | 0.44 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.44 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1410858 | 1.00 | ACE2 (0.55) | ACE2ALDH1A1TSHRGPR84CA1 | |
| SCHEMBL1410439 | 0.98 | ACE2 (0.52) | ACE2ALDH1A1TSHRGPR84CA1 | |
| SCHEMBL1410690 | 0.91 | ALDH1A1 (0.46) | ACE2ALDH1A1TSHRGPR84CA1 | |
| SCHEMBL9176733 | 0.91 | ALDH1A1 (0.46) | ACE2ALDH1A1TSHRGPR84CA1 | |
| SCHEMBL495224 | 0.83 | ALDH1A1 (0.50) | ACE2ALDH1A1TSHRFFAR1TP53 | |
| SCHEMBL495837 | 0.83 | ALDH1A1 (0.50) | ACE2ALDH1A1TSHRFFAR1TP53 | |
| SCHEMBL494115 | 0.83 | ALDH1A1 (0.50) | ACE2ALDH1A1TSHRFFAR1TP53 | |
| SCHEMBL495367 | 0.83 | ALDH1A1 (0.50) | ACE2ALDH1A1TSHRFFAR1TP53 | |
| SCHEMBL495207 | 0.83 | ALDH1A1 (0.50) | ACE2ALDH1A1TSHRFFAR1TP53 | |
| SCHEMBL495635 | 0.83 | ALDH1A1 (0.50) | ACE2ALDH1A1TSHRFFAR1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180028649-A1 | SYNTHETIC GLUCOPYRANOSYL LIPID ADJUVANTS | INFECTIOUS DISEASE RESEARCH INSTITUTE (US) | 2018-02-01 | — | — | US | disclosed |
| US-9814772-B2 | Synthetic glucopyranosyl lipid adjuvants | INFECTIOUS DISEASE RESEARCH INSTITUTE (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170182155-A1 | SYNTHETIC GLUCOPYRANOSYL LIPID ADJUVANTS | INFECTIOUS DISEASE RES INST (US) | 2017-06-29 | — | — | US | disclosed |
| US-9480740-B2 | Synthetic glucopyranosyl lipid adjuvants | INFECTIOUS DISEASE RESEARCH INSTITUTE (US) | 2016-11-01 | — | — | US | disclosed |
| US-8916133-B2 | Fluorinated 2-amino-4-(benzylamino)phenylcarbamate derivatives | SCIFLUOR LIFE SCIENCES, LLC (US) | 2014-12-23 | — | — | US | disclosed |
| US-20140322268-A1 | SYNTHETIC GLUCOPYRANOSYL LIPID ADJUVANTS | INFECTIOUS DISEASE RESEARCH INSTITUTE (US) | 2014-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140322268-A1 | SYNTHETIC GLUCOPYRANOSYL LIPID ADJUVANTS | B3GAT3, GLA, LGALS8 | ACE2 1201/4885ALDH1A1 3976/4885TSHR 1791/4885 |
| US-20180028649-A1 | SYNTHETIC GLUCOPYRANOSYL LIPID ADJUVANTS | B3GAT3, GLA, LGALS8 | ACE2 1174/4885ALDH1A1 3967/4885TSHR 1803/4885 |
| US-20170182155-A1 | SYNTHETIC GLUCOPYRANOSYL LIPID ADJUVANTS | B3GAT3, GLA, LGALS8 | ACE2 1201/4885ALDH1A1 3976/4885TSHR 1791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.